Re: Looks like a new version of OxyContin is on the way...

Dear IMH,

I haven't done any research on the tamper proof Oxy (though I should) but I
have a sneaking suspicion they will take one of the best pain medications on
the market and twist and pervert for the sake of a minority of fools who
choose to abuse the medication. I need only point out Opana, which should
have been one hell of a lot more effective than Oxycontin (being
oxymorphone- a long lasting step up from Dilaudid) which they ruined with
their new Time-N (I think that's what they call it) matrix. Instead of
reaching a peak level in the bloodstream, medication levels fluctuate so
rapidly from high to low, one half of the time it's working, the other half
it's not. People experiencing chronic pain need a medication that peaks and
maintains a high level, not a daily rollercoaster ride of pain.
On the flip side, if what I've read long ago on their idea with oxycontin,
to surround the time released oxycodone with a shell of naltrexalone (a sort
of anti narcotic released when a junkie crushes the pill) it may very well
help the chronic constipation we experience. Methadone patients in a test
program were give the most minute of injections of naltrexerone, not enough
to effect the maintenance effects of the methadone, and within 30 seconds
every one of them ran for the bathroom. They didn't publish the average
amount of weight loss, but I would bet it was sizeable.
I apologize, but it just burns my ass that we, the legitimate majority, have
to make concessions in the quality of our pain care for a handful of junkies
who waste the lives we could be living in a healthy and productive manner.
They want the drugs, give them the pain too. We'll see exactly what the
price of a buzz is worth.

Fuming--og

--
Be Sure to Check Out the PAYNE HERTZ blog, for people with chronic pain, by
people with chronic pain.
join in at: http://paynehertz.blogspot.com


"I M Hurting" <Damn@xxxxxxxxxxxxxxx> wrote in message
news:vtnsu31gdk5391qe148as1e6ifi6ofgdol@xxxxxxxxxx
Apparently a new abuse-resistant version of OxyContin from Purdue
Pharma will arrive before too long. Hope it is as effective at
relieving pain as the "classic" version.

I wonder what this will do to the generics?

Maybe this would be a good time to buy Purdue stock!

http://biz.yahoo.com/ap/080327/king_pharma_mover.html?.v=2

Here is the text if you don't want to use the link:

King Pharma Stock Drops on Remoxy Threat
Thursday March 27, 4:29 pm ET
By Marley Seaman, AP Business Writer
King Shares Hit Two-Year Low After FDA Says It Will Meet to Discuss
New Version of Oxycontin

NEW YORK (AP) -- King Pharmaceuticals shares traded Thursday at their
lowest levels in almost three years on the news that a rival pain drug
may reach the market ahead of King's Remoxy.

According to a notice posted on the Food and Drug Administration Web
site, an FDA panel will meet on May 5 to review a drug application
from Purdue Pharma LP. The topic of the review will be a new, extended
release tablet of Purdue's painkiller Oxycontin. King's Remoxy is a
similar abuse-resistant painkiller.

While Remoxy is in late stage clinical testing, Purdue has filed a new
drug application for its new version of Oxycontin, indicating its
product is further along in development and could reach the market
first.

King shares fell 45 cents, or 5 percent, to close at $8.58. Earlier,
the stock fell to $8.26, its lowest price since May 2005.

Natixis Bleichroeder analyst Corey Davis said Purdue is at least one
year ahead of King, as the panel meeting is "uncontested proof" that
Purdue has filed its new drug application.

Both companies are trying to develop versions of the drug that are
more difficult to abuse than Oxycontin. The time-release mechanism of
Oxycontin can be "defeated" if it is crushed and snorted or dissolved
in alcohol.

Remoxy contains oxycodone, the active ingredient in Oxycontin, inside
a viscuous formula. King is developing the drug with Pain Therapeutics
Inc.

Pain Therapeutics shares fell 81 cents, or 9.4 percent, to close at
$7.77.


IMH


.

Quantcast